Autolus Therapeutics (AUTL) Price & Analysis

Compare

787 Followers

AUTL Stock Chart & Stats

$1.49

-$0.14(-5.56%)

At close: Jan 08 4:00 PM EST

$1.49

-$0.14(-5.56%)

Day’s Range― - ―

52-Week Range$1.11 - $2.97

Previous CloseN/A

Volume359.61K

Average Volume (3M)3.29M

Market Cap

$412.52M

Enterprise Value$390.08M

Total Cash (Recent Filing)$367.41M

Total Debt (Recent Filing)$65.83M

Price to Earnings (P/E)―

Beta1.37

Next Earnings

Mar 10, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding266,143,280

10 Day Avg. Volume5,048,520

30 Day Avg. Volume3,287,823

Financial Highlights & Ratios

PEG Ratio0.10

Price to Book (P/B)1.40

Price to Sales (P/S)59.25

P/FCF Ratio-2.49

Enterprise Value/Market Cap0.95

Enterprise Value/Revenue7.63

Enterprise Value/Gross Profit-2.47

Enterprise Value/Ebitda-1.55

Forecast

1Y Price Target

$7.68

Price Target Upside415.44% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-0.96

Revenue Forecast (FY)$75.21M

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessInitial results from the Phase Ib CATULUS study in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia show a 96% response rate and consistent safety profile, supporting advancement into the Phase II portion of the study.

Market ExpansionMarket expansion into pediatric ALL and lupus nephritis can push Aucatzyl to blockbuster market opportunity, and the differentiated safety and efficacy profile of Aucatzyl will continue to drive market share conversion.

Product PerformanceThe real-world analysis showed all patients received both doses of Aucatzyl, and physicians were comfortable treating older patients with Aucatzyl than Tecartus, suggesting strong market share gains since commercial launch.

Bears Say

Clinical UncertaintyIt remains unclear if longer B-cell aplasia translates into more durable clinical responses.

Sales PerformanceSales were flat due to changes in CMS leading to a slowdown in patients.

Stock Price DeclineAutolus shares are down roughly 13% following the earnings release, with sales coming in below consensus in the quarter and yet COGS coming in above estimates.

Autolus Therapeutics News

Autolus Therapeutics presents data from CATULUS Phase 1 trial of obe-cel

Autolus Therapeutics (AUTL) announces presentation of preliminary data from the CATULUS Phase 1 trial of obe-cel in pediatric...

3d ago

AUTL

Autolus Therapeutics appoints Ryan Richardson to board of directors

Autolus Therapeutics (AUTL) announced the appointment of Ryan Richardson to the Company’s Board of Directors. Richardson previously served...

10d ago

AUTL

Midday Fly By: Alphabet continues ascent, fueled by AI optimism

Stocks were drifting and searching for direction early this morning following a strong tech-driven rally yesterday, but the...

16d ago

Autolus Therapeutics announces NICE draft guidance recommending Aucatzyl

Autolus Therapeutics (AUTL) announced that the National Institute for Health and Care Excellence has published draft guidance recommending...

16d ago

AUTL

Midday Fly By: AMD sees acceleration, IBM unveils quantum processor

The major averages were mixed near noon, with the Dow Jones Industrial Average hitting a record high as...

29d ago

Autolus Therapeutics reports Q3 EPS (30c), consensus (23c)

Reports Q3 revenue $21.144M, consensus $21.31M. “Through three quarters of launch, we are encouraged by our progress to...

29d ago

AUTL

Autolus Therapeutics Appoints Ryan Richardson to Board

Autolus Therapeutics ( ($AUTL) ) has shared an update. On December 1, 2025, Autolus Therapeutics announced the appointment...

9d ago

AUTL

Autolus Therapeutics Reports Q3 2025 Financial Results

Autolus Therapeutics ( ($AUTL) ) has released its Q3 earnings. Here is a breakdown of the information Autolus...

28d ago

AUTL

Autolus Therapeutics’ Earnings Call: Mixed Sentiments

Autolus Therapeutics (($AUTL)) has held its Q3 earnings call. Read on for the main highlights of the call....

28d ago

AUTL

Autolus Therapeutics: Strong Buy Rating Backed by Growth Potential and Strategic Advancements

Needham analyst Gil Blum maintained a Buy rating on Autolus Therapeutics today and set a price target of...

29d ago

AUTL

Autolus Therapeutics: Promising Growth and Market Expansion Justify Buy Rating

William Blair analyst Matt Phipps has reiterated their bullish stance on AUTL stock, giving a Buy rating on...

29d ago

AUTL

Autolus Therapeutics Appoints New Principal Accounting Officer

Autolus Therapeutics ( ($AUTL) ) has provided an announcement. On November 7, 2025, Autolus Therapeutics announced the resignation...

29d ago

AUTL

AUTL Upcoming Earnings Report: What to Expect?

Autolus Therapeutics (AUTL) is scheduled to report 3rd quarter earnings on 11/12/2025, before the market opens. Regarding Q3...

1M ago

AUTL

Autolus Therapeutics to present data at ASH Meeting

Autolus Therapeutics (AUTL) announces the online publication of five abstracts submitted to the American Society of Hematology, ASH,...

1M ago

AUTL

AUTL FAQ

What was Autolus Therapeutics Plc’s price range in the past 12 months?

Autolus Therapeutics Plc lowest stock price was $1.10 and its highest was $2.97 in the past 12 months.

What is Autolus Therapeutics Plc’s market cap?

Autolus Therapeutics Plc’s market cap is $412.52M.

When is Autolus Therapeutics Plc’s upcoming earnings report date?

Autolus Therapeutics Plc’s upcoming earnings report date is Mar 10, 2026 which is in 89 days.

How were Autolus Therapeutics Plc’s earnings last quarter?

Autolus Therapeutics Plc released its earnings results on Nov 12, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.214 by -$0.086.

Is Autolus Therapeutics Plc overvalued?

According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Autolus Therapeutics Plc pay dividends?

Autolus Therapeutics Plc does not currently pay dividends.

What is Autolus Therapeutics Plc’s EPS estimate?

Autolus Therapeutics Plc’s EPS estimate is -0.23.

How many shares outstanding does Autolus Therapeutics Plc have?

Autolus Therapeutics Plc has 266,143,280 shares outstanding.

What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?

Autolus Therapeutics Plc reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.214. Following the earnings report the stock price went down -9.333%.

Which hedge fund is a major shareholder of Autolus Therapeutics Plc?

Currently, no hedge funds are holding shares in AUTL

Autolus Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-60.52%

Trailing 12-Months

Asset Growth

-20.01%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Autolus Therapeutics Plc

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Autolus Therapeutics (AUTL) Earnings & Revenues

Historic Earnings Reports

AUTL Company Deck

AUTL Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

While the company has seen a successful launch of Obe-cel in the U.S. with significant market penetration and expansion into new clinical areas, financial challenges such as high cost of sales and increased operational losses present notable challenges. However, the company is well-capitalized to continue its growth and expansion strategies.View all AUTL earnings summaries

AUTL Stock 12 Month Forecast

Average Price Target

$7.68

▲(415.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","11":"$11","2.75":"$2.75","5.5":"$5.5","8.25":"$8.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.68,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.68</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2.75,5.5,8.25,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,2.043076923076923,2.706153846153846,3.3692307692307693,4.032307692307692,4.695384615384615,5.358461538461539,6.021538461538461,6.684615384615385,7.347692307692308,8.010769230769231,8.673846153846153,9.336923076923078,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,1.8646153846153846,2.3492307692307692,2.833846153846154,3.3184615384615386,3.803076923076923,4.287692307692307,4.772307692307692,5.256923076923076,5.741538461538461,6.226153846153846,6.71076923076923,7.195384615384615,{"y":7.68,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.38,1.6584615384615384,1.936923076923077,2.2153846153846155,2.493846153846154,2.7723076923076926,3.0507692307692307,3.329230769230769,3.6076923076923078,3.8861538461538463,4.164615384615384,4.443076923076923,4.7215384615384615,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.26,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.73,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.91,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.29,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.67,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >